{"created":"2023-07-27T06:44:17.008290+00:00","id":34456,"links":{},"metadata":{"_buckets":{"deposit":"a1101cb2-d522-49a4-a62f-2d2aecbbe541"},"_deposit":{"created_by":3,"id":"34456","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"34456"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00034456","sets":["2812:2813:2818"]},"author_link":["83290","3019"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-06-13","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"5p.","bibliographicVolumeNumber":"2013-04-01 – 2016-03-31","bibliographic_titles":[{"bibliographic_title":"平成27(2015)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2015 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"去勢抵抗性前立腺癌が進行すると、その後の治療に難渋する。従来ドセタキセルを中心とした抗癌剤が有効であったが、それを使用した後は予後不良である。我々は、フラボノイドの一種である2’-hydroxyflavanone (2’-HF)を使用して、前立腺癌細胞に対する効果を調査した。2’-HFはアンドロゲン感受性前立腺癌細胞LNCaPだけでなく、アンドロゲン非依存性前立腺癌細胞PC-3、DU145においても抗腫瘍効果を示した。さらに、LNCaPにおいてPSA promoterによって誘導されるルシフェラーゼアッセイを行ったところ、2’-HFはアンドロゲンによるアンドロゲン受容体活性亢進を阻害した。","subitem_description_type":"Abstract"},{"subitem_description":"After progression of CRPC during hormonal treatment and docetaxel treatment, we face difficulty of these treatments. Therefore, it is important to develop new medicines　next to taxanes. Then we focused on one of flavonoids, 2’-hydroxyflavanone (2’-HF). 2’-HF inhibited not only cell proliferation of androgen-sensitive prostate cancer LNCaP but also androgen-independent prostate cancer cells PC-3 and DU145. We also examined effect of 2’-HF on androgen receptor (AR) activity. When LNCaP cells transfected with PSA promoter-driven luciferase reporter were treated with 2’-HF in the presence of androgen, AR activity was reduced by 2’-HF. These data indicate that 2’-HF is candidate to treat CRPC after docetaxel treatment.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:25462472, 研究期間(年度):2013-04-01 – 2016-03-31","subitem_description_type":"Other"},{"subitem_description":"出典：「フラボノイドを用いた前立腺癌再燃の予防とドセタキセル感受性増強への応用」研究成果報告書　課題番号25462472\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所）） \n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-25462472/25462472seika/）を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00034443","subitem_identifier_reg_type":"JaLC"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=50248580","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-25462472/","subitem_relation_type_select":"URI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-25462472/25462472seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-05"}],"displaytype":"detail","filename":"ME-PR-MIZOKAMI-A-kaken 2016-5p.pdf","filesize":[{"value":"2.0 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-MIZOKAMI-A-kaken 2016-5p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/34456/files/ME-PR-MIZOKAMI-A-kaken 2016-5p.pdf"},"version_id":"819d0e23-5761-4679-a134-42cdcd47be49"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"フラボノイドを用いた前立腺癌再燃の予防とドセタキセル感受性増強への応用","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"フラボノイドを用いた前立腺癌再燃の予防とドセタキセル感受性増強への応用"},{"subitem_title":"Prevention of CRPC and application for docetaxel treatment using flavonoids","subitem_title_language":"en"}]},"item_type_id":"9","owner":"3","path":["2818"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-05"},"publish_date":"2017-10-05","publish_status":"0","recid":"34456","relation_version_is_last":true,"title":["フラボノイドを用いた前立腺癌再燃の予防とドセタキセル感受性増強への応用"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T11:05:14.400491+00:00"}